Clinical trial · Interventional
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
An Open-Label, Multicenter, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study objective of this open label, multicenter study is to provide access to NKTR-102 treatment to subjects previously enrolled in a NKTR-102 study who are without signs of disease progression since receiving NKTR-102. In addition the study will evaluate the safety of continued exposure to NKTR-102, observe disease status and survival status in subjects receiving NKTR-102, and evaluate the efficacy of NKTR-102 in subjects with advanced or metastatic solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Solid Tumor | Malignant Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NKTR-102 120 mg/m2 | Drug | — | UNRESOLVED |
| NKTR-102 145 mg/m2 | Drug | — | UNRESOLVED |
| NKTR-102 50 mg/m2 | Drug | — | UNRESOLVED |
| NKTR-102 95 mg/m2 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- NKTR-102
- interventionNames
- Drug: NKTR-102 145 mg/m2
- Drug: NKTR-102 120 mg/m2
- Drug: NKTR-102 95 mg/m2
- Drug: NKTR-102 50 mg/m2
Primary outcomes (1)
- measure
- Length of Exposure to NKTR-102
- timeFrame
- Screening, Every 21 day cycle of treatment and Quarterly Follow-up
- description
- To provide access to NKTR-102 to subjects who previously received NKTR-102 in a clinical trial and were without signs of disease progression since receiving NKTR-102.
Secondary outcomes (3)
- measure
- Adverse Events
- timeFrame
- Screening, Every 21 day cycle of treatment and Quarterly Follow-up
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion: 1. Received prior treatment with NKTR-102 2. Free of disease progression since receiving NKTR-102 3. Adequate bone marrow and organ function 4. Treatment with NKTR-102 in the extension study to begin within 8 weeks after receipt of their of last dose of NKTR-102 5. Agree to use adequate contraception Exclusion: 1. Treatment with other anti-cancer therapy between the last dose of NKTR-102 in the prior study and before first dose of NKTR-102 in the extension study 2. A toxicity that requires a 3rd dose reduction after taking NKTR-102 or are scheduled to receive a dose \< 70 mg/m2 upon entry into this study 3. Pregnancy or lactation
References
Publications (0)
Data not yet available